Indian medtech firm replaces passive dressings with silk

This article is a part of Startup Spotlight, a series that features young, up-and-coming startups.

Photo credit: Fibroheal

While buying a saree for his mother, Vivek Mishra became curious about silk’s structural properties. He collaborated with a plastic surgeon to explore the material’s clinical potential. This led to the launch of Fibroheal to develop tissue regeneration technology.

😟 Problem

Conventional wound dressings act as passive coverings that fail to actively support biological tissue regeneration. This approach causes prolonged healing and higher infection risks for complex and chronic wounds.

Furthermore, India imports 85% of its advanced wound-care solutions. This reliance on foreign medical devices keeps treatment costs high for local healthcare systems and patients.

💡 Solution

The startup converts silk fibroin into functional biomaterials that interact directly with the wound environment. These solutions actively facilitate the body’s natural healing processes.

The proprietary platform enables several clinical capabilities, including: 

• Accelerates tissue regeneration and wound closure.
• Supports cellular attachment and migration.
• Maintains moisture balance during the healing cycle.
• Controls infections through the sustained release of nano-silver.
• Deploys as powders, gels, sheets, and hemostatic sprays.

Image credit: Fibroheal

📊 Market size

The Indian advanced wound-care market is projected to reach US$445 million by 2025. The company targets 5,000 to 8,000 high-volume hospitals domestically.

Wound treatments require recurring consumable purchases. This dynamic allows a single institutional account to generate ongoing revenue over a multi-year relationship.

🤝 Team

• Vivek Mishra. Co-founder and CEO. He previously worked across the pharma, agritech, and clinical nutrition sectors.
• Bharat Tandon. Co-founder and director. He previously built the animal health company Vetcare. 

🚀 Traction

• Supplies wound-care products to over 500 hospitals across India.
• Treated more than 200,000 patients with its biomaterial solutions.
• Secured nine patents for its proprietary silk-protein technology.
• Deployed its hemostatic technology during military and emergency operations.
• Established partnerships with over 30 collaborations with industry, academic, and research institutions globally. 

🏆 Competition

💰 Financials

🚩 Risks